Financial News

Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

SciSparc Ltd. - Ordinary Shares (NQ:SPRC)

0.3057 -0.0102 (-3.23%)
Streaming Delayed Price Updated: 2:07 PM EDT, May 19, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about SciSparc Ltd. - Ordinary Shares

< Previous 1 2 3 4 5 6 7 8 9
...
13 14 Next >
Autism CBD Trial Enrolls Children: This Israeli Co. Is Making Headway In New Treatments
The first patient has been enrolled in SciSparc Ltd.'s clinical trial evaluating the effectiveness and safety of their CBD-based drug for treating children with autism spectrum disorder, marking a... 
Via Benzinga
Topics Intellectual Property
Exposures Intellectual Property
SciSparc Announces Enrollment of First Patient for its Clinical Trial for Children with Autism Spectrum Disorder
From SciSparc Ltd
Via GlobeNewswire
SciSparc Granted Patent for Core Technology in Multiple Jurisdictions in Europe
From SciSparc Ltd
Via GlobeNewswire
Why Is SciSparc (SPRC) Stock Up 50% Today?
News of an investment fund inking an equity purchase agreement with SciSparc is boosting underlying credibility and lifting SPRC stock. 
Via InvestorPlace
Why Is SciSparc (SPRC) Stock Up 25% Today?
With SciSparc announcing positive results stemming from its joint venture, the drug discovery implications are boosting SPRC stock. 
Via InvestorPlace
What's Going On With SciSparc Ltd Stock?
SciSparc Ltd. (NASDAQ: SPRC) shares are trading higher Wednesday. 
Via Benzinga
SciSparc Issued Canadian Patent for Opioids Reduction Use in Pain Management Technology
From SciSparc Ltd
Via GlobeNewswire
Psyched: New Evidence Shows Psilocybin As Anxiety Therapy, Open-Source Learning For Therapists, Enveric's Licensing Deals And More
Via Benzinga
SciSparc Delivers Treatment for Autism Spectrum Disorder Clinical Trial Enabling Commencement of Dosing
From SciSparc Ltd
Via GlobeNewswire
SciSparc-Clearmind Partnership Yields Three New International Patent Applications for MDMA, Ibogaine and Ketamine Compounds
From SciSparc Ltd
Via GlobeNewswire
Clearmind Medicine Submits Three Additional International Patent Applications for Innovative MDMA, Ibogaine and Ketamine Compounds
From Clearmind Medicine Inc.
Via GlobeNewswire
EXCLUSIVE: Psychedelic-Focused Firm Clearmind Medicine Submits Three New International Patent Applications For MDMA, Ibogaine And Ketamine Compounds
Patent applications by Clearmind Medicine for novel compositions in collaboration with SciSparc. Clearmind's CEO, highlights the significant expansion of IP protection. 
Via Benzinga
Topics Intellectual Property
Exposures Intellectual Property
Next-Gen Psychedelics Companies SciSparc And Clearmind Collaboration File 3 Patents
SciSparc & Clearmind file patents for LSD, psilocybin, DMT blends, advancing psychedelic therapeutics for mental health. 
Via Benzinga
Topics Intellectual Property
Exposures Intellectual Property
What's Going On With Psychedelic Drug-Developers SciSparc And Clearmind Stock?
SciSparc Ltd. and Clearmind Medicine Inc. shares are trading higher Tuesday after the companies announced the submission of three international patent applications as part of the ongoing collaboration... 
Via Benzinga
Topics Intellectual Property
Exposures Intellectual Property
Why Fluor Shares Are Trading Lower By Around 8%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Shares of Fluor Corporation (NYSE: FLR) fell during Tuesday’s session following fourth-quarter results. 
Via Benzinga
Clearmind Medicine Submits Three International Patent Applications for Next Generation Classic Psychedelic-Based Compounds
From Clearmind Medicine Inc.
Via GlobeNewswire
SciSparc and Clearmind Continue to Strengthen International Patent Portfolio with Next Generation Classic Psychedelic-Based Compounds
From SciSparc Ltd
Via GlobeNewswire
SciSparc Announces Initiation of Patient Recruitment for its Clinical Trial with SCI-210 in Children with Autism Spectrum Disorder
From SciSparc Ltd
Via GlobeNewswire
Psychedelics Headlines: Anti-inflammatory Effects, Global Drug Survey, 'Synthetic Surprise,' UK's Harm Reduction Hub And More
Discover the latest research on psychedelics, from anti-inflammatory effects to end-of-life therapy. New journal issue and online course available. 
Via Benzinga
Why BlackBerry Shares Are Trading Lower By Over 17%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Shares of BlackBerry Limited (NYSE: BB) fell sharply during Wednesday’s session after the company announced a proposed private offering of $160 million of convertible senior notes. BlackBerry shares... 
Via Benzinga
Crude Oil Rises Over 1%; DuPont Shares Plunge
U.S. stocks traded higher midway through trading, with the Nasdaq Composite gaining around 150 points on Wednesday. The Dow traded up 0.36% to 38,040.66 while the NASDAQ rose 0.97% to 15,574.97. The... 
Via Benzinga
Topics Stocks
Exposures Fossil Fuels US Equities
Why SciSparc Stock Is Lighting Up
SciSparc Ltd. shares are trading higher Wednesday after the company announced that it has entered into a standby equity purchase agreement with YA II PN, Ltd., a fund managed by Yorkville Advisors... 
Via Benzinga
Dow Jumps 100 Points; Netflix Reports Strong Q4 Sales
U.S. stocks traded higher this morning, with the Dow Jones index gaining more than 100 points on Wednesday. Following the market opening Wednesday, the Dow traded up 0.29% to 38,013.76 while the NASDAQ... 
Via Benzinga
Topics Stocks
Exposures US Equities
SciSparc Ltd. Announces $20 Million Standby Equity Purchase Agreement
From SciSparc Ltd
Via GlobeNewswire
SciSparc Advances the Acquisition Process of a Leading Vehicle Importer Company in Israel with the provision of a Bridge Loan of $1.4 million
From SciSparc Ltd
Via GlobeNewswire
Why Is Clearmind (CMND) Stock Up 40% Today?
The jump in Clearmind sent its market cap to $6 million. The study of psychedelic compounds to treat mental illness is growing. 
Via InvestorPlace
SciSparc and Clearmind Medicine Reflect on Successful Collaboration in 2023 Aiming to Upgrade Wide Range of Psychedelic-Based Treatments
From SciSparc Ltd
Via GlobeNewswire
Clearmind Medicine and SciSparc Reflect on Successful Collaboration in 2023 Aiming to Upgrade Wide Range of Psychedelic- Based Treatments
From Clearmind Medicine Inc.
Via GlobeNewswire
Why Despegar.com Shares Are Trading Higher By Over 16%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Shares of Despegar.com, Corp. (NYSE: DESP) rose sharply during Wednesday’s session after the company raised its FY23 financial guidance. The company said it now sees revenue of $690 million to $700... 
Via Benzinga
SciSparc Announces Positive Results for MitoCareX Bio with its Drug Discovery Platform
From SciSparc Ltd
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 9
...
13 14 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.

Use the myMotherLode.com Keyword Search to go straight to a specific page

Popular Pages

  • Local News
  • US News
  • Weather
  • State News
  • Events
  • Traffic
  • Sports
  • Dining Guide
  • Real Estate
  • Classifieds
  • Financial News
  • Fire Info
Terms of Service Privacy Policy
© Copyright 2000-2019 Clarke Broadcasting Corporation. All rights reserved.
Feedback